124 related articles for article (PubMed ID: 27619981)
21. Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor.
Rauvala M; Puistola U; Turpeenniemi-Hujanen T
Gynecol Oncol; 2005 Dec; 99(3):656-63. PubMed ID: 16112717
[TBL] [Abstract][Full Text] [Related]
22. Amplification of the epidermal growth factor receptor gene in glioblastoma: an analysis of the relationship between genotype and phenotype by CISH method.
Miyanaga T; Hirato J; Nakazato Y
Neuropathology; 2008 Apr; 28(2):116-26. PubMed ID: 18021194
[TBL] [Abstract][Full Text] [Related]
23. Role of tissue inhibitors of metalloproteinases (TIMPs) in colorectal carcinoma.
Joo YE; Seo KS; Kim J; Kim HS; Rew JS; Park CS; Kim SJ
J Korean Med Sci; 1999 Aug; 14(4):417-23. PubMed ID: 10485622
[TBL] [Abstract][Full Text] [Related]
24. The prognostic role of tissue and serum MMP-1 and TIMP-1 expression in patients with non-small cell lung cancer.
An HJ; Lee YJ; Hong SA; Kim JO; Lee KY; Kim YK; Park JK; Kang JH
Pathol Res Pract; 2016 May; 212(5):357-64. PubMed ID: 26995105
[TBL] [Abstract][Full Text] [Related]
25. Surrogate markers predict angiogenic potential and survival in patients with glioblastoma multiforme.
Greenfield JP; Jin DK; Young LM; Christos PJ; Abrey L; Rafii S; Gutin PH
Neurosurgery; 2009 May; 64(5):819-26; discussion 826-7. PubMed ID: 19404145
[TBL] [Abstract][Full Text] [Related]
26. C-MET overexpression and amplification in gliomas.
Kwak Y; Kim SI; Park CK; Paek SH; Lee ST; Park SH
Int J Clin Exp Pathol; 2015; 8(11):14932-8. PubMed ID: 26823824
[TBL] [Abstract][Full Text] [Related]
27. Primary glioblastomas with and without EGFR amplification: relationship to genetic alterations and clinicopathological features.
Benito R; Gil-Benso R; Quilis V; Perez M; Gregori-Romero M; Roldan P; Gonzalez-Darder J; Cerdá-Nicolas M; Lopez-Gines C
Neuropathology; 2010 Aug; 30(4):392-400. PubMed ID: 20051017
[TBL] [Abstract][Full Text] [Related]
28. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
[TBL] [Abstract][Full Text] [Related]
29. Circulating levels of matrix metalloproteinases MMP-3 and MMP-1, tissue inhibitor of metalloproteinases 1 (TIMP-1), and MMP-1/TIMP-1 complex in rheumatic disease. Correlation with clinical activity of rheumatoid arthritis versus other surrogate markers.
Keyszer G; Lambiri I; Nagel R; Keysser C; Keysser M; Gromnica-Ihle E; Franz J; Burmester GR; Jung K
J Rheumatol; 1999 Feb; 26(2):251-8. PubMed ID: 9972954
[TBL] [Abstract][Full Text] [Related]
30. [Expression and clinical significance of MMP-2, MMP-9,TIMP-1, and TIMP-2 in breast carcinoma].
Fan SQ; Wei QY; Li MR; Zhang LQ; Liang QC
Ai Zheng; 2003 Sep; 22(9):968-73. PubMed ID: 12969531
[TBL] [Abstract][Full Text] [Related]
31. Tissue inhibitor of metalloproteinases-1 in the postoperative monitoring of colorectal cancer.
Holten-Andersen MN; Nielsen HJ; Sørensen S; Jensen V; Brünner N; Christensen IJ
Eur J Cancer; 2006 Aug; 42(12):1889-96. PubMed ID: 16809030
[TBL] [Abstract][Full Text] [Related]
32. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma.
Pelloski CE; Mahajan A; Maor M; Chang EL; Woo S; Gilbert M; Colman H; Yang H; Ledoux A; Blair H; Passe S; Jenkins RB; Aldape KD
Clin Cancer Res; 2005 May; 11(9):3326-34. PubMed ID: 15867231
[TBL] [Abstract][Full Text] [Related]
33. MET immunolabelling is a useful predictive tool for MET gene amplification in glioblastoma.
Burel-Vandenbos F; Ngo-Mai M; Dadone B; Di Mauro I; Gimet S; Saada-Bouzid E; Bourg V; Almairac F; Fontaine D; Virolle T; Pedeutour F
Neuropathol Appl Neurobiol; 2017 Apr; 43(3):252-266. PubMed ID: 26946354
[TBL] [Abstract][Full Text] [Related]
34. Identification of potential serum biomarkers of glioblastoma: serum osteopontin levels correlate with poor prognosis.
Sreekanthreddy P; Srinivasan H; Kumar DM; Nijaguna MB; Sridevi S; Vrinda M; Arivazhagan A; Balasubramaniam A; Hegde AS; Chandramouli BA; Santosh V; Rao MR; Kondaiah P; Somasundaram K
Cancer Epidemiol Biomarkers Prev; 2010 Jun; 19(6):1409-22. PubMed ID: 20530493
[TBL] [Abstract][Full Text] [Related]
35. Tissue inhibitor of metalloproteinase-1 levels in plasma from tumour arteries and veins of patients with rectal cancer.
Frederiksen C; Lykke J; Christensen IJ; Brünner N; Nielsen HJ
Scand J Clin Lab Invest; 2007; 67(5):545-52. PubMed ID: 17763191
[TBL] [Abstract][Full Text] [Related]
36. Elevated serum levels of type I collagen degradation marker ICTP and tissue inhibitor of metalloproteinase (TIMP) 1 are associated with poor prognosis in lung cancer.
Ylisirniö S; Höyhtyä M; Mäkitaro R; Pääakkö P; Risteli J; Kinnula VL; Turpeenniemi-Hujanen T; Jukkola A
Clin Cancer Res; 2001 Jun; 7(6):1633-7. PubMed ID: 11410500
[TBL] [Abstract][Full Text] [Related]
37. Detrended fluctuation analysis of genome-wide copy number profiles of glioblastomas using array-based comparative genomic hybridization.
Nakahara Y; Shiraishi T; Okamoto H; Mineta T; Oishi T; Sasaki K; Tabuchi K
Neuro Oncol; 2004 Oct; 6(4):281-9. PubMed ID: 15494095
[TBL] [Abstract][Full Text] [Related]
38. Serum TIMP-1 in gastric cancer patients: a potential prognostic biomarker.
Wang CS; Wu TL; Tsao KC; Sun CF
Ann Clin Lab Sci; 2006; 36(1):23-30. PubMed ID: 16501233
[TBL] [Abstract][Full Text] [Related]
39. A comparative study of tissue inhibitor of metalloproteinases-1 levels in plasma and tumour tissue from patients with primary breast cancer and in plasma from patients with metastatic breast cancer.
Schrohl AS; Mueller V; Christensen IJ; Pantel K; Thomssen C; Bruenner N
Tumour Biol; 2008; 29(3):181-7. PubMed ID: 18645261
[TBL] [Abstract][Full Text] [Related]
40. Profiles of matrix metalloproteinases and their inhibitors in plasma of patients with dementia.
Lorenzl S; Buerger K; Hampel H; Beal MF
Int Psychogeriatr; 2008 Feb; 20(1):67-76. PubMed ID: 17697439
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]